Advertisement

The potential role for phage therapy for genetic modification of cutaneous diseases

      Abstract

      Antimicrobial resistance has become increasingly common across the globe, claiming more than 33,000 lives annually in Europe and 35,000 lives in the United States alone. The problem lies in trying to find potential solutions capable of tackling resistance and being able to fight infections that may resist various antimicrobials. Since Alexander Fleming's discovery in 1928, every antimicrobial synthesized in the past 70 years has developed at least one or more strains of resistant bacteria. One particular alternative to antimicrobials has brought hope to many in the scientific community: the bacteriophage. Bacteriophages are viruses that can replicate within bacteria, triggering genetic alterations and changes in pathways of protein expression by encoding a few to hundreds of genes within their genomes. The bacteriophage can hijack the cell, using the cell's genetic apparatus to replicate within the bacterium until bacterial lysis occurs. This therapy has been used in the genodermatosis Netherton syndrome, which has been associated with the increased risk of Staphylococcus aureus infections. Emerging data support the potential role of bacteriophage therapy for Cutibacterium acnes in acne vulgaris, with a potential role in genetic disorders with severe acne vulgaris, including Apert syndrome. Bacteriophages hold benefits for genodermatoses associated with recurrent cutaneous infections, that is, the immunodeficiencies with distinctive cutaneous features as well as conditions such as atopic dermatitis, in which bacterial colonization plays a strong role.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Clinics in Dermatology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Geddes A.
        80th anniversary of the discovery of penicillin an appreciation of Sir Alexander Fleming.
        Int J Antimicrob Agents. 2008; 32: 373
        • Arseculeratne SN
        • Arseculeratne G.
        A re-appraisal of the conventional history of antibiosis and penicillin.
        Mycoses. 2017; 60: 343-347
        • Fleming RS
        • Queen FB.
        Penicillin resistance; of bacteria; strain variations in penicillin sensitivity among bacterial species encountered in war wounds and infections.
        Am J Clin Pathol. 1946; 16: 63-65
      1. Frieden T. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States, 2013. Available at: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf. Accessed January 20, 2021.

        • Levy SB
        • Marshall B.
        Antibacterial resistance worldwide: causes, challenges, and responses.
        Nat Med. 2004; 10: S122-S129
        • Jassim A
        • Limoges R.
        Natural solution to antibiotic resistance: bacteriophages “The Living Drugs.
        World J Microbiol Biotechnol. 2014; 30: 2153-2170
        • Hiltunen T
        • Virta M
        • Laine AL.
        Antibiotic resistance in the wild: an eco-evolutionary perspective.
        Philos Trans R Soc Lond B Biol Sci. 2017; 37220160039
        • Peterson E
        • Kaur P.
        Bacteria: relationships between resistance determinants of antibiotic producers, environmental bacteria, and clinical pathogens.
        Front Microbiol. 2018; 9: 2928
        • Kasman LM
        • Porter LD
        Bacteriophages.
        ([Updated 2019 Feb 20])StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL)2019
        • Chanishvili N.
        Phage therapy–history from Twort and d'Herelle through Soviet experience to current approaches.
        Adv Virus Res. 2012; 83: 3-40
        • Castillo DE
        • Nanda S
        • Keri JE.
        Propionibacterium (cutibacterium) acnes bacteriophage therapy in acne: current evidence and future perspectives.
        Dermatol Ther (Heidelb). 2019; 9: 19-31
        • Zhvania P
        • Hoyle NS
        • Nadareishvili L
        • Nizharadze D
        • Kutateladze M.
        Phage therapy in a 16-year-old boy with netherton syndrome.
        Front Med (Lausanne). 2017; 4: 94
        • Chu JJK
        • Poh WH
        • Hasnuddin NTB
        • Hew EY
        • Dam LC
        • Sahili AE
        • Rice SA
        • Goh BC
        Novel Phage Lysin Abp013 against Acinetobacter baumannii.
        Antibiotics (Basel). 2022; 11: 169
        • Schooley RT
        • Biswas B
        • Gill JJ
        • et al.
        Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant acinetobacter baumannii infection.
        Antimicrob Agents Chemother. 2017; 61 (-17): e00954
      2. https://www.niaid.nih.gov/search/cognitive?search=bacteriophage, accessed 3/10/22.

        • Dall C.
        New center aims to advance bacteriophage therapy.
        Center for Infectious Disease Research and Policy, University of Minnesota, 22 June 2018 (Available at:) (Accessed July 1, 2019)
      3. LaFee S, Buschman H. With OK from FDA, UC San Diego researchers prepare to launch novel phage study. Available at: https://health.ucsd.edu/news/releases/Pages/2019-01-08-FDA-okays-uc-san-diego-to-launch-novel-phage-study.aspx. Accessed January 20, 2020.

        • Hauser AR
        • Mecsas J
        • Moir DT.
        Beyond antibiotics: new therapeutic approaches for bacterial infections.
        Clin Infect Dis. 2016; 63: 89-95
        • Zaenglein AL
        • Pathy AL
        • Schlosser BJ
        • et al.
        Guidelines of care for the management of acne vulgaris.
        J Am Acad Dermatol. 2016; 74: 945-973
        • Shimamori Y
        • Pramono AK
        • Kitao T
        • et al.
        Isolation and characterization of a novel phage SaGU1 that infects staphylococcus aureus clinical isolates from patients with atopic dermatitis.
        Curr Microbiol. 2021; 78: 1267-1276
        • Shimamori Y
        • Mitsunaka S
        • Yamashita H
        • et al.
        Staphylococcal phage in combination with staphylococcus epidermidis as a potential treatment for staphylococcus aureus-associated atopic dermatitis and suppressor of phage-resistant mutants.
        Viruses. 2020; 13: 7
        • Furfaro LL
        • Payne MS
        • Chang BJ.
        Bacteriophage therapy: clinical trials and regulatory hurdles.
        Front Cell Infect Microbiol. 2018; 8: 376
        • Bragg R
        • van der Westhuizen W
        • Lee JY
        • Coetsee E
        • Boucher C.
        Bacteriophages as potential treatment option for antibiotic resistant bacteria.
        Ad Exp Med Biol. 2014; 807: 97-110
        • Moelling K
        • Broecker F
        • Willy C.
        A wake-up call: we need phage therapy now.
        Viruses. 2018; 10: E688
        • Loc-Carrillo C
        • ST Abedon
        Pros and cons of phage therapy.
        Bacteriophage. 2011; 1: 111-114
        • Abedon ST.
        Phage therapy: various perspectives on how to improve the art.
        Methods Mol Biol. 2018; 1734: 113-127
        • Pirnay JP
        • Blasdel BG
        • Bretaudeau L
        • et al.
        Quality and safety requirements for sustainable phage therapy products.
        Pharm Res. 2015; 32: 2173-2179